8-K 1 d737947d8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 2, 2014

Heron Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware |  | 001-33221 |  | 94-2875566
(State or other jurisdiction of incorporation) |  | (Commission File Number) |  | (I.R.S. Employer Identification No.)

123 Saginaw Drive Redwood City CA |  | 94063
(Address of principal executive offices) |  | (Zip Code)

Registrant’s telephone number, including area code (650) 366-2626

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ |  | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ |  | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ |  | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ |  | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 | Other Events.

On June 2, 2014, Heron Therapeutics, Inc. (the “Company”) issued a press release regarding the Company’s planned resubmission of its NDA for SUSTOL™. A copy of the press release is attached hereto as Exhibit 99.1.

The Company will deliver a corporate presentation at the Jefferies Healthcare Conference on June 2, 2014. The slides from the presentation are attached hereto as Exhibit 99.2. The attached materials have also been posted on the Company’s website at www.herontx.com. The Company does not undertake to update this presentation.

ITEM 9.01 | Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. |  | Description
99.1 |  | Press Release, dated June 2, 2014
99.2 |  | Corporate Presentation, dated June 2, 2014

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  |  |  |  |  | Heron Therapeutics, Inc.
Date: June 2, 2014 |  |  |  |  |  | /s/ Brian G. Drazba
|  |  |  |  |  | Brian G. Drazba
|  |  |  |  |  | Vice President, Finance and Chief Financial Officer

3